Please login to the form below

Not currently logged in


This page shows the latest QALY news and features for those working in and with pharma, biotech and healthcare.

ICER says Alnylam’s Onpattro should cost 90%-95% less

ICER says Alnylam’s Onpattro should cost 90%-95% less

Even at that level, ICER says the therapy far exceeds commonly accepted thresholds of $50, 000-$150, 000 per quality-adjusted life year (QALY) at $850, 000 per QALY gained, and

Latest news

More from news
Approximately 2 fully matching, plus 112 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest from PMHub

  • Tracking comms trends: communication and market access

    Measures like progression-free survival and cost per QALY are not easy concepts to convey to the non-medically trained. ... The real challenge lies in finding a better approach, while avoiding the QALY, to bring additional clarity into the discussion of

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...